Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012998 | 0.87 | CCR5 (0.69) | CCR5 | |
| SCHEMBL13969447 | 0.87 | CCR5 (0.68) | CCR5 | |
| SCHEMBL4018881 | 0.85 | CCR5 (0.55) | CCR5 | |
| SCHEMBL4551935 | 0.78 | CCR5 (0.56) | CCR5 | |
| SCHEMBL4205772 | 0.78 | CCR5 (0.83) | CCR5 | |
| SCHEMBL4551923 | 0.77 | CCR5 (0.65) | CCR5 | |
| SCHEMBL13946593 | 0.77 | CCR5 (0.71) | CCR5 | |
| SCHEMBL4552558 | 0.77 | CCR5 (0.47) | CCR5 | |
| SCHEMBL4209312 | 0.73 | CCR5 (0.56) | CCR5 | |
| SCHEMBL3934835 | 0.72 | CCR5 (0.72) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090028818-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-01-29 | — | — | US | disclosed |
| WO-2009013171-A2 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028818-A1 | Heterocyclic antiviral compounds | CCR5, CCR1, CCR2 | CCR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.